The Swiss GLP Monitoring Authorities

Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Federal Department of Home Affairs DHA
Federal Office of Public Health FOPH

Federal Department of the Environment, Transport, Energy and Communications DETEC
Federal Office for the Environment FOEN

swissmedic

Swissmedic
Swiss Agency for Therapeutic Products

Statement of GLP Compliance

According to Art. 14 paragraph 3 Ordinance on Good Laboratory Practice [SR 813.112.1]

It is hereby confirmed that

during the period of **07 - 08 March 2006**

the following test facility of **Institute for Biopharmaceutical Research (IBR), Inc.**
Lauchefeld 31
CH-9548 Matzingen

was inspected by the Swiss Agency for Therapeutic Products with respect to the compliance with the Swiss Ordinance on Good Laboratory Practice, adopted on 18th May 2005 [SR 813.112.1]. This Ordinance is based on the OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted on 26th November 1997 by decision of the OECD Council [C(97)186/Final].

Test Facility:	Areas of expertise:
Institute for Biopharmaceutical Research (IBR), Inc.	• **Mutagenicity studies** • **Analytical and clinical chemistry testing**

The above mentioned test facility is listed in the GLP Register and is inspected on a regular basis. Based on the decision dated 12th May 2006 it can be confirmed that the above mentioned test facility is able to conduct studies according to the aforementioned areas of expertise in compliance with the principles of GLP.

Swiss Federal Office of Public Health
Consumer Protection Directorate
Notification Authority for Chemicals
The Head

FEDERAL OFFICE OF PUBLIC HEALTH

Dag Kappes

Bern, 20th June 2006

Dr. Dag Kappes